4-methylsalicylic acid

We are 4-methylsalicylic acid CAS:50-85-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 4-methylsalicylic acid
CAS.NO:50-85-1
Synonyms:
2-Hydroxy-4-methylbenzoic acid,m-Cresotic acid
Benzoic acid, 2-hydroxy-4-methyl-
m-Cresotic acid
4-Methylsalicylic acid
2-Hydroxy-p-toluic Acid
2-Hydroxy-4-methylbenzoic Acid

Molecular Formula:C8H8O3
Molecular Weight: 152.14700

Physical and Chemical Properties:
Density:1.3±0.1 g/cm3
Boiling point: 315.2±30.0 °C at 760 mmHg
Melting point: /
Flash point:158.6±21.1 °C
Refractive index: 1.600

Specification:
Appearance: White or off-white powder
Purity:≥99%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Repaglinide CAS:135062-02-1

Related News: Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.88962-86-1 Pharmaceutical intermediates and APIs belong to the fine chemical industry.3-methyl-7H-xanthine CAS:1076-22-8 The iLet Bionic Pancreas System is a pocket-sized, wearable investigational medical device that is designed to autonomously control blood-sugar levels.4-Fluoro-2-methylbenzonitrile CAS:147754-12-9 Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment.Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.